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Abstract
Na+/K+-ATPase alpha 2 (Atp1a2) is an integral plasma membrane protein belonging to the P-type ATPase family
that is responsible for maintaining the sodium (Na+) and potassium (K+) gradients across cellular membranes with
hydrolysis of ATP. Atp1a2 contains two subunits, alpha and beta, with each having various isoforms and differential
tissue distribution. In humans, mutations in ATP1A2 are associated with a rare form of hereditary migraines with
aura known as familial hemiplegic migraine type II. Genetic studies in mice have revealed other neurological effects
of Atp1a2 in mice including anxiety, fear, and learning and motor function disorders. This paper reviews the recent
findings in the literature concerning Atp1a2.
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Introduction
The integral plasma membrane protein Na+/K+-ATPase
is a member of the P-type ATPase family. P-type
ATPases maintain the essential plasma membrane po-
tential in all eukaryotic cells and are found in all cell
type membranes. The plasma membrane potential is up-
held by adjusting ion concentrations on the intracellular
and extracellular sides of the membrane. This electro-
chemical gradient fuels central cellular processes, such
as the secondary transport of metabolites, and it also
provides the basis for electrical excitation in neurons.
The mechanism of action of Na+/K+-ATPase involves a
conformation change driven by ATP hydrolysis (Figure 1).
While bound to ATP, the pump binds three intracellular
sodium ions (Figure 1, step 1). ATP is then hydrolyzed to
ADP, and the pump is phosphorylated at a highly conserved
aspartate residue (Figure 1, step 2). This phosphorylation
causes a conformation change, resulting in the release of
the sodium ions into the extracellular space and the
binding of two potassium ions (Figure 1, step 3). This
binding of potassium ions causes the pump to dephos-
phorylate (Figure 1, step 4), which returns the pump to its
previous conformational state (Figure 1, step 5), and trans-
ports the potassium ions into the cell (Figure 1, step 6).
The process then repeats itself when ATP again binds
to the pump.
The Na+/K+-ATPases consist of an α subunit and a β
subunit and, only in the kidney, a γ subunit [1,4]. The α
and β subunits are synthesized separately, assembled in
the endoplasmic reticulum, and are delivered to the
plasma membrane [1,5]. The α subunit is the catalytic
region of the enzyme and contains the binding sites for
the sodium and potassium ions, ATP, and cardiac glyco-
sides such as ouabain, while the glycosylated β subunit is
needed for proper folding and function of the catalytic
subunit. The X-ray crystal structure of Na+/K+-ATPase was
examined from pig kidney, which showed the binding sites
in the α subunit and the interactions between the α and β
subunits [6]. Different genes encode each of the multiple α
and β isoforms and the γ isoform; four α isoforms
(ATP1A1, ATP1A2, ATP1A3, and ATP1A4), four β isoforms
(ATP1B1, ATP1B2, ATP1B3 and ATP1B4), and one γ iso-
form (FXYD2) have been identified (Table 1, [7,8]).
The α isoforms differ in tissue distribution and are regu-
lated developmentally [9]. The α1 subunit is expressed
ubiquitously, the α2 isoform is expressed in the brain,
heart, and skeletal muscle, the α3 subunit is expressed in
the brain and heart, and the α4 isoform is expressed in
sperm and its precursor cells [10,11]. The four isoforms
have a high degree of amino acid identity but have differ-
ences in kinetic properties and substrate affinity [12,13].
Homology between human and mouse protein is between
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83% and 99%, and within subunits and species, it is
approximately between 80% and 90% (Table 1) [14]. In
the adult brain, the α1 isoform is found in multiple
central nervous system (CNS) cell types, the α2 isoform
is primarily expressed in astrocytes and pyramidal
cells in the hippocampus, and α3 is expressed only in
neurons [15-17].
ATP1A2, as well as the other isoforms, is responsible
for maintaining the resting membrane potential and
for driving nutrient and neurotransmitter uptakes.
Na+/K+-ATPases are important in clearing extracellular
potassium during neuronal activity and are essential in the
clearance of released glutamate in the synaptic cleft
because reuptake in astrocytes and neurons is driven
by the sodium and potassium gradients [18]. ATP1A2
is co-localized with other ion transporters, such as the
sodium/calcium (Na+/Ca2+) exchanger and the glutamate
transporter, which are important in the clearance of
glutamate and potassium from the extracellular space
in the CNS [19-21].
The role of ATP1A2 in FHM2
Familial hemiplegic migraine (FHM) is a rare autosomal
dominant form of migraine with aura. FHM attacks are
generally longer than the common migraine with aura;
however, they share similar symptoms (Table 2, [22])
including visual, sensory, motor, and aphasia [23]. Aura
symptoms are different for each person but are generally
described as disturbances in light perception, such as
spots or lines in vision, and changes in sensory percep-
tion, such as heightened sensitivity to smells and sounds
[24]. There are three types of FHM: type 1 is associated
with mutations in the neuronal calcium channel gene
and is the most prevalent form of FHM, type 2 is caused
by mutations present in ATP1A2, and type 3 is a rare
form of FHM related to mutations in the sodium chan-
nel gene [24].
FHM2 patients suffer from migraines with hemiplegia
and partial paralysis during the aura phase and, in some
cases, accompanied by seizures or cognitive dysfunction.
Neuroimaging studies have shown that migraine aura is
caused by cortical spreading depression (CSD). CSD is a
wave of continual strong neuronal depolarization that
slowly progresses across the cortex, generating a brief
intense spike of activity that is followed by long-lasting
neural suppression [25]. CSD has been shown to activate
the trigeminovascular system (TGVS), which is respon-
sible for the headache associated with migraines [24]. In-
hibition of ATP1A2 leads to high levels of extracellular
potassium, causing neurons to become depolarized which
can cause CSD [26].
ATP1A2 was identified as a gene associated with
FHM2 in 2003 in two Italian families [27]. The muta-
tions and deficiencies in ATP1A2 that cause FHM2 are
responsible for approximately 20% of FHM in families
[2]. There are over 50 mutations in ATP1A2 that have
Figure 1 The Na+/K+-ATPase reaction cycle. The sequence of steps
involved in the active transport of Na+ and K+ ions. See text for details
[1-3].
Table 1 Na+/K+-ATPases in the P-type ATPase family in the human and mouse
Type Human Location (chr:bp) Size (#AA) Mouse Location (chr:bp) Size (#AA) Homology (%)
α1 ATP1A1 1:116915795 1023 Atp1a1 3:101576219 1023 97
α2 ATP1A2 1:160085520 1020 Atp1a2 1:172271709 1020 99
α3 ATP1A3 19:42470734 1013 Atp1a3 7:24978167 1013 99
α4 ATP1A4 1:160121352 1029 Atp1a4 1:172223508 1032 83
β1 ATP1B1 1:169075947 303 Atp1b1 1:164437267 304 94
β2 ATP1B2 17:7554254 290 Atp1b2 11:69599750 290 97
β3 ATP1B3 3:141595470 279 Atp1b3 9:96332673 278 73
β4 ATP1B4 X:119495940 357 Atp1b4 X:38316267 356 89
γ FXYD2 11:117690790 64 Fxyd2 9:45399709 64 81
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been identified in association with FHM2. Almost all
FHM2 mutations are non-synonymous SNPs, but there
are also small deletions [28] and a mutation affecting the
stop codon, causing an extension of the ATP1A2 protein
by 27 amino acid residues [29]. Most of the mutations
are associated with pure FHM without additional clinical
symptoms [27-31]. Recently, a number of ATP1A2 muta-
tions were reported to be associated with FHM and
cerebellar problems, specifically motor problems [32],
childhood convulsions [33], epilepsy [29,34], and mental
retardation [29,35]. Some ATP1A2 mutations have been
shown to be associated with non-hemiplegic migraine
phenotypes, such as basilar migraine [36] and the com-
mon migraine [37].
One of the most important experimental drugs to
study ATP1A2, as well as ATP1A1 and ATP1A3, is oua-
bain which is a plant-derived steroid that binds to the
E2P form of Na
+/K+-ATPases, as seen in Figure 1. Oua-
bain acts as a non-selective antagonist and inhibits the
enzyme transport activity [38]. The three isoforms in
humans show similar affinity for ouabain; however, oua-
bain binding is altered due to changes in extracellular
potassium levels, resulting in varying sensitivities [39]. In
rats, Atp1a3 is very sensitive to ouabain, Atp1a2 is less
sensitive, and Atp1a1 is insensitive [40].
Cell-based studies have shown that multiple individual
mutations in ATP1A2 result in dysfunctional ion pump
activity. The functional effects of mutations in ATP1A2
have been studied in HeLa cells and Xenopus oocytes
(Table 3). Recombinant ATP1A2 subunits containing
mutations that cause the pump to be insensitive to ouabain
were expressed in HeLa cells; the ouabain-insensitive
mutants were used to distinguish between endogenous
ATP1A2 activity and the effects of other mutations
engineered into the recombinant ATP1A2 [27,33,35,41,42].
Three mutations in HeLa cells and two mutations in
Xenopus oocytes produced severe or complete loss of
function of pump activity, which led to cell death
[3,27,35,41]. Five other FHM2 mutants were analyzed,
and pump activity was reduced but sufficient to allow
survival of the HeLa cells [41-43].
ATP1A2 is expressed primarily in astrocytes in the
adult, where it appears functionally coupled to various
transporters (glutamate transporter and Na+/Ca2+
exchanger), and is essential in the clearance of released
glutamate and potassium from the extracellular space dur-
ing neuronal activity. FHM2 mutations that cause loss of
function of ATP1A2 may lead to decreased glutamate
clearance and an increase of potassium in the synaptic
cleft during neuronal activity, which could lead to
prolonged recovery time after neuronal excitation, and
may render the brain to be more susceptible to CSD
[23,26].
There are two hypothesized mechanisms for the ef-
fects of ATP1A2 mutations. First, the mutations cause
an increase in extracellular potassium, which can result
in the impaired clearance of potassium ions and there-
fore induce CSD [43]. Second, since the distribution of
ATP1A2 is co-localized with the Na+/Ca2+ exchanger,
the mutations to ATP1A2 would cause intracellular so-
dium to increase, which increases intracellular calcium
levels through the Na+/Ca2+ exchanger, similar to FHM1,
resulting in glutamate release and a decrease in glutamate
clearance which can also lead to CSD [23,44]. Both hy-
potheses result in making the brain more susceptible to
CSD and therefore migraines with aura.
Currently, the medications used to treat FHM2 are
standard migraine prophylactic drugs, such as antide-
pressants, beta blockers, and calcium channel blockers
[45], which treat the symptoms, not the cause. Further
investigation of ATP1A2 in humans and animal models
are needed to better determine treatment options.
Atp1a2 studies in animal models
Over the last 20 years, animal studies using either
Atp1a2 knock-out or knock-in mutations have increased
our understanding of its effect on behavior. Atp1a2
heterozygous mice have been studied by two separate
groups, one at the University of Cincinnati led by Dr.
Jerry Lingrel and the second at Jichi Medical School in
Japan overseen by Dr. Kiyoshi Kawakami. Both groups
have shown that modulation of Atp1a2 activity affects
neural activity and whole animal behavior. More re-
cently, a group led by Giorgio Casari at the Vita-Salute
San Raffaele University and Center for Translational
Genomics and Bioinformatics in Italy generated the first
FHM2 knock-in mouse. The constructs for the gene
alterations are shown in Figure 2.
Lingrel's lab has been investigating the functional roles
of the various Na+/K+-ATPase isoforms for over 20
years. This lab developed heterozygous mice for Atp1a2
as well as for Atp1a1 and Atp1a3 [19]. Atp1a2 heterozy-
gous (Atp1a2±) mice were tested for differences in be-
havior as well as to investigate the role of Atp1a2 in the
heart. Kawakami's group also created an Atp1a2± mouse
by deleting a portion of the gene, resulting in only one
functioning copy [18]. They examined the role of Atp1a2
in neural activity by measuring fear and anxiety in
Table 2 International Headache Society migraine criterion
Repeated episodic headache features within 4 to 72 h
Any two of the following Any one of the following
Unilateral Nausea and/or vomiting
Throbbing Photophobia and phonophobia
Worsened by movement
Moderate or severe
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heterozygous mice. The Atp1a2 heterozygous mice also
showed hyperphagia during the light period and suffered
from late onset obesity [46]. The homozygous null Atp1a2
mice are neonatally lethal due to lack of synchronized neur-
onal firing in the breathing center of the brain [16,47,48],
and the Atp1a2± mice have approximately half the protein
compared to with wild type [19].
The heterozygous mice from both groups consistently
show an anxiety-related phenotype (Table 4). The Atp1a2±
mice were hypoactive compared with the wild type based
on measurements of total distance traveled and time spent
in the corners of the open-field testing box [17]. They also
spent less time in and had fewer entries into the open arm
of the plus maze [11,17,41]. In the light/dark test, the
knock-outs spent less time in the light compartment and
had fewer transitions between the two compartments [18].
Taken together, these results show that the Atp1a2± mice
are more anxious than the wild type.
Learning and memory behavioral tests were interpreted
differently between the two groups. The Lingrel lab
examined spatial learning and memory using the Morris
water maze and found that the knock-out mouse had a
longer latency to find the hidden platform, suggesting
that they have impaired learning. The Kawakami lab
studied the knock-out mouse in the conditioned fear
test, which showed that the knock-out mouse had
increased freezing time which is typically interpreted
as improved learning and memory [18]. However,
the authors concluded that the knock-out mouse had
enhanced fear; other effects such as increased learning
and memory and altered sensory perception could explain
the results. The authors did not examine or control these
other possibilities.
The role of Atp1a2 has also been examined in the
hearts of the heterozygous mice. While the hearts were
histologically the same in Atp1a2± and wild-type mice,
the Atp1a2± mice had hypercontractile hearts [19,41,42].
As noted above, the Atp1a2± mice have 50% less
protein than the wild type, and reduction of Atp1a2
alters calcium levels in cardiomyocytes, suggesting that
Figure 2 Three separate groups have mutated the Atp1a2 gene in mice. Two groups created knock-outs through disruption of the gene at
two different locations and the other has created a knock-in mutation to mimic one of the FHM2 mutations in exon 19. Atp1a2 is located in the
antisense strand of chromosome 1 [18,19,26].
Table 3 Cell-based studies demonstrating the effect of ATP1A2 mutations in Xenopus oocytes and HeLa cells
Cell type Mutation Effect on pump function Reference
HeLa L764P Complete loss [2,3,27]
W887R Complete loss [2,3,27]
G615R Complete loss [27]
R593W Reduced rate [2,41,42]
V628M Reduced rate [2,41,42]
T345A Similar to wild-type: lower affinity for potassium [2,41,42]
M731T Similar to wild-type: decreased catalytic turnover and increased affinity for potassium [2,41,42]
R689Q Similar to wild-type: decreased catalytic turnover and increased affinity for potassium [2,41,42]
Xenopus oocytes L764P Complete loss [43]
W887R Complete loss [43]
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the intracellular concentration of sodium ions would
increase. This increased concentration results in an
increase in intracellular calcium levels because the
sodium-calcium exchanger is inhibited by the high
intracellular sodium levels. The excess intracellular cal-
cium causes the contractions in the cardiomyocytes to
increase in strength [19,41]. These results suggest that
Atp1a2 regulates calcium levels and, therefore, contract-
ibility in the heart.
The group at the Vita-Salute San Raffaele University
and Center for Translational Genomics and Bioinformat-
ics in Italy has generated the first FHM2 knock-in
mouse. This mouse model was created by inserting the
T2763C mutation, in exon 19 of the mouse, which is
one of the first mutations that was associated with
FHM2 [26,41,42]. The T2763C mutation causes the
amino acid substitution W887R, which affects the β
subunit binding site in Atp1a2, resulting in a misfolding
of the protein and, in cell-based studies, a complete loss
of pump function. The homozygous knock-in mice are
neonatally lethal, similar to the knock-out mice de-
scribed previously; therefore, heterozygous knock-in
mice were used for experiments. The authors suggested
that because the W887R mutant protein does not trans-
locate efficiently to the plasma membrane, it is degraded
via the proteasome, which results in reduced overall
protein in the brain. The knock-in mice were tested for
CSD by electrical stimulation, and results showed that
they were more susceptible to CSD: they had a higher
threshold and velocity but equal duration of CSD than
the wild type. These results may be due to the impaired
clearance of extracellular potassium and glutamate by
astrocytes, which is comparable to the effects of FHM2
mutations in humans [23,26]. Further testing on this
mouse model will be beneficial to understanding the
mechanism of at least this mutation in FHM and pos-
sible treatment avenues.
Conclusions
Mutations and deficiencies in Atp1a2 are associated
with FHM2 in patients suffering from migraines with
hemiplegia and partial paralysis during the aura phase.
FHM2 patients may also have increased susceptibility to
CSD, which may be due to the increase in extracellular
potassium and/or a decrease in glutamate clearance.
CSD has been shown to cause the aura coupled with mi-
graines and may activate the TGVS, resulting in the
headache portion of a migraine.
Studies in Atp1a2-deficient mice suggest an associ-
ation of the protein with anxiety, learning disorders, and
fear. Multiple groups have created knock-out and
knock-in heterozygous Atp1a2 mice and have tested
them for fear and anxiety, locomotor activity, learning
ability, and susceptibility to CSD. The results of these
animal studies show significant increased anxiety and
fear, reduced locomotor activity, and increased suscepti-
bility to CSD in heterozygous Atp1a2 mice compared
with the wild type. Learning and memory results are not
consistent between the two heterozygous mouse studies.
The Lingrel lab results showed poor learning and mem-
ory in the Morris water maze; however, the Kawakami
lab found that the heterozygous mice had increased
Table 4 Testing in the Atp1a2 heterozygous mice
Test Phenotype
measured
Parameters measured Heterozygous compared
with wild type
Lab
Hidden platform Learning and
memory
Latency time Decreased Lingrel
Elevated zero maze Anxiety Time spent in open arms Decreased Lingrel
Entries into open quadrant Decreased
Open-field activity Anxiety Time spent in corners Increased Lingrel
Total distance traveled Decreased Lingrel and Kawakami
Light/dark Anxiety Path length in light compartment Decreased Kawakami
Time spent in light compartment Decreased
Latency to first entry into light
compartment
Increased
Number of transitions between light
and dark
Decreased
Elevated plus maze Anxiety Time in open arms Decreased Kawakami
Entries into open arms Decreased
Conditioned fear stimuli Fear and learning Freezing time Increased Kawakami
Cardiac performance Hypercontractile heart Contractibility Increased Lingrel
The various tests, parameter measured, and results were compared with the wild type [17,18].
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freezing during the conditioned fear stimuli which could
be due to increased fear and anxiety, increased sensory
perception, or improved learning and memory. Add-
itional animal studies with the knock-in mutations asso-
ciated with FHM2 and the Atp1a2 knock-outs are
needed to better understand FHM2, treatment options,
and its overall effect on behavior.
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